SAFC Introduces New Media System
The system is compatible with a wide range of industrial CHO cell lines.
SAFC announced on Apr. 7, 2015 that the company has introduced a new fed-batch medium, EX-CELL Advanced CHO Fed-batch System. The new basal media, available with and without glucose, is said to offer “high titers, robust scalability, and uncompromised protein quality,” according to a statement.
"At SAFC we recognize our customers' needs are constantly changing," said Deb Stutz, director of biopharm marketing at SAFC. "We are delighted to launch this product in response to market needs for new levels of speed and performance, while continuing to provide the confidence of a secure and transparent supply chain."
Fed-batch production processes have improved upstream process titers dramatically in recent years. According to some sources, companies have been able to attain antibody concentrations of up to 10–13 g/L using fed-batch processes. Although batch-fed stainless steel bioreactors remain the preferred choice for the commercial manufacture of therapeutics, according to research by BioPlan Associates, continuous bioprocessing is also emerging as a viable option for upstream activities.
Source: SAFC
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
